PMC:7565482 / 24371-25470 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T109","span":{"begin":237,"end":241},"obj":"Body_part"},{"id":"T110","span":{"begin":438,"end":442},"obj":"Body_part"},{"id":"T111","span":{"begin":809,"end":813},"obj":"Body_part"},{"id":"T112","span":{"begin":902,"end":906},"obj":"Body_part"},{"id":"T113","span":{"begin":929,"end":934},"obj":"Body_part"}],"attributes":[{"id":"A109","pred":"fma_id","subj":"T109","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A110","pred":"fma_id","subj":"T110","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A111","pred":"fma_id","subj":"T111","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A112","pred":"fma_id","subj":"T112","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A113","pred":"fma_id","subj":"T113","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"The present study is currently limited to the design of the CoV-2 consensus sequence, without functional immune analyses of the OLP sets in samples from infected individuals. However, the principal aim here was to provide a SARS-CoV-2 T cell test reagent, including all described ORF and covering as much viral variability as possible, for its implementation in future screening efforts. In addition, the OLP sets will certainly elicit T cell responses in vitro as partial evaluation has been performed by others in studies using peptides spanning some of the regions covered by the present consensus sequence [5,9,11] and since the current peptide designs (length, overlap) has been shown to be effective in the past [55,70]. Thus, the present peptide designs will afford a high-resolution analysis of the T cell response to SARS-CoV-2, the nature of the targeted epitopes and the functionality and T cell receptor use of the T cells targeting these epitopes, thereby increasing our knowledge of factors that drive COVID-19 disease progression and which could be implemented in vaccine development."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T64","span":{"begin":224,"end":232},"obj":"Disease"},{"id":"T65","span":{"begin":826,"end":834},"obj":"Disease"},{"id":"T66","span":{"begin":1016,"end":1024},"obj":"Disease"}],"attributes":[{"id":"A64","pred":"mondo_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A65","pred":"mondo_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A66","pred":"mondo_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"The present study is currently limited to the design of the CoV-2 consensus sequence, without functional immune analyses of the OLP sets in samples from infected individuals. However, the principal aim here was to provide a SARS-CoV-2 T cell test reagent, including all described ORF and covering as much viral variability as possible, for its implementation in future screening efforts. In addition, the OLP sets will certainly elicit T cell responses in vitro as partial evaluation has been performed by others in studies using peptides spanning some of the regions covered by the present consensus sequence [5,9,11] and since the current peptide designs (length, overlap) has been shown to be effective in the past [55,70]. Thus, the present peptide designs will afford a high-resolution analysis of the T cell response to SARS-CoV-2, the nature of the targeted epitopes and the functionality and T cell receptor use of the T cells targeting these epitopes, thereby increasing our knowledge of factors that drive COVID-19 disease progression and which could be implemented in vaccine development."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T221","span":{"begin":198,"end":201},"obj":"http://purl.obolibrary.org/obo/PR_000001343"},{"id":"T222","span":{"begin":222,"end":223},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T223","span":{"begin":233,"end":241},"obj":"http://purl.obolibrary.org/obo/CLO_0001272"},{"id":"T224","span":{"begin":242,"end":246},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T225","span":{"begin":436,"end":442},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T226","span":{"begin":484,"end":487},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T227","span":{"begin":530,"end":538},"obj":"http://purl.obolibrary.org/obo/PR_000018263"},{"id":"T228","span":{"begin":641,"end":648},"obj":"http://purl.obolibrary.org/obo/PR_000018263"},{"id":"T229","span":{"begin":675,"end":678},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T230","span":{"begin":745,"end":752},"obj":"http://purl.obolibrary.org/obo/PR_000018263"},{"id":"T231","span":{"begin":773,"end":774},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T232","span":{"begin":807,"end":813},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T233","span":{"begin":900,"end":906},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T234","span":{"begin":927,"end":934},"obj":"http://purl.obolibrary.org/obo/CL_0000084"}],"text":"The present study is currently limited to the design of the CoV-2 consensus sequence, without functional immune analyses of the OLP sets in samples from infected individuals. However, the principal aim here was to provide a SARS-CoV-2 T cell test reagent, including all described ORF and covering as much viral variability as possible, for its implementation in future screening efforts. In addition, the OLP sets will certainly elicit T cell responses in vitro as partial evaluation has been performed by others in studies using peptides spanning some of the regions covered by the present consensus sequence [5,9,11] and since the current peptide designs (length, overlap) has been shown to be effective in the past [55,70]. Thus, the present peptide designs will afford a high-resolution analysis of the T cell response to SARS-CoV-2, the nature of the targeted epitopes and the functionality and T cell receptor use of the T cells targeting these epitopes, thereby increasing our knowledge of factors that drive COVID-19 disease progression and which could be implemented in vaccine development."}

{"project":"LitCovid-PubTator","denotations":[{"id":"309","span":{"begin":60,"end":65},"obj":"Species"},{"id":"310","span":{"begin":224,"end":234},"obj":"Species"},{"id":"311","span":{"begin":826,"end":836},"obj":"Species"},{"id":"312","span":{"begin":153,"end":161},"obj":"Disease"},{"id":"313","span":{"begin":1016,"end":1024},"obj":"Disease"}],"attributes":[{"id":"A309","pred":"tao:has_database_id","subj":"309","obj":"Tax:2697049"},{"id":"A310","pred":"tao:has_database_id","subj":"310","obj":"Tax:2697049"},{"id":"A311","pred":"tao:has_database_id","subj":"311","obj":"Tax:2697049"},{"id":"A312","pred":"tao:has_database_id","subj":"312","obj":"MESH:D007239"},{"id":"A313","pred":"tao:has_database_id","subj":"313","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The present study is currently limited to the design of the CoV-2 consensus sequence, without functional immune analyses of the OLP sets in samples from infected individuals. However, the principal aim here was to provide a SARS-CoV-2 T cell test reagent, including all described ORF and covering as much viral variability as possible, for its implementation in future screening efforts. In addition, the OLP sets will certainly elicit T cell responses in vitro as partial evaluation has been performed by others in studies using peptides spanning some of the regions covered by the present consensus sequence [5,9,11] and since the current peptide designs (length, overlap) has been shown to be effective in the past [55,70]. Thus, the present peptide designs will afford a high-resolution analysis of the T cell response to SARS-CoV-2, the nature of the targeted epitopes and the functionality and T cell receptor use of the T cells targeting these epitopes, thereby increasing our knowledge of factors that drive COVID-19 disease progression and which could be implemented in vaccine development."}

{"project":"LitCovid-sentences","denotations":[{"id":"T167","span":{"begin":0,"end":174},"obj":"Sentence"},{"id":"T168","span":{"begin":175,"end":387},"obj":"Sentence"},{"id":"T169","span":{"begin":388,"end":726},"obj":"Sentence"},{"id":"T170","span":{"begin":727,"end":1099},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The present study is currently limited to the design of the CoV-2 consensus sequence, without functional immune analyses of the OLP sets in samples from infected individuals. However, the principal aim here was to provide a SARS-CoV-2 T cell test reagent, including all described ORF and covering as much viral variability as possible, for its implementation in future screening efforts. In addition, the OLP sets will certainly elicit T cell responses in vitro as partial evaluation has been performed by others in studies using peptides spanning some of the regions covered by the present consensus sequence [5,9,11] and since the current peptide designs (length, overlap) has been shown to be effective in the past [55,70]. Thus, the present peptide designs will afford a high-resolution analysis of the T cell response to SARS-CoV-2, the nature of the targeted epitopes and the functionality and T cell receptor use of the T cells targeting these epitopes, thereby increasing our knowledge of factors that drive COVID-19 disease progression and which could be implemented in vaccine development."}